nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—SLC6A2—locus ceruleus—bipolar disorder	0.0405	0.188	CbGeAlD
Droxidopa—DDC—telencephalic ventricle—bipolar disorder	0.0404	0.187	CbGeAlD
Droxidopa—SLC6A2—autonomic nervous system—bipolar disorder	0.0215	0.1	CbGeAlD
Droxidopa—DDC—blood plasma—bipolar disorder	0.0192	0.0893	CbGeAlD
Droxidopa—PAH—nervous system—bipolar disorder	0.01	0.0466	CbGeAlD
Droxidopa—PAH—brain—bipolar disorder	0.00767	0.0356	CbGeAlD
Droxidopa—ADRA2A—blood plasma—bipolar disorder	0.00648	0.0301	CbGeAlD
Droxidopa—DDC—nervous system—bipolar disorder	0.00572	0.0265	CbGeAlD
Droxidopa—SLC16A10—thyroid gland—bipolar disorder	0.00466	0.0216	CbGeAlD
Droxidopa—ADRA1B—nervous system—bipolar disorder	0.00451	0.0209	CbGeAlD
Droxidopa—ADRA1D—nervous system—bipolar disorder	0.00441	0.0205	CbGeAlD
Droxidopa—DDC—brain—bipolar disorder	0.00437	0.0203	CbGeAlD
Droxidopa—Methyldopa—COMT—bipolar disorder	0.00434	0.138	CrCbGaD
Droxidopa—ADRA2C—adrenal cortex—bipolar disorder	0.00412	0.0191	CbGeAlD
Droxidopa—SLC16A10—cerebellum—bipolar disorder	0.00369	0.0171	CbGeAlD
Droxidopa—L-DOPA—DRD5—bipolar disorder	0.00361	0.115	CrCbGaD
Droxidopa—ADRA1B—brain—bipolar disorder	0.00345	0.016	CbGeAlD
Droxidopa—ADRA1D—brain—bipolar disorder	0.00337	0.0156	CbGeAlD
Droxidopa—Dopamine—DRD5—bipolar disorder	0.00336	0.106	CrCbGaD
Droxidopa—ADRB1—nervous system—bipolar disorder	0.0032	0.0149	CbGeAlD
Droxidopa—SLC6A2—nervous system—bipolar disorder	0.00273	0.0126	CbGeAlD
Droxidopa—ADRA1A—nervous system—bipolar disorder	0.00253	0.0118	CbGeAlD
Droxidopa—ADRB1—brain—bipolar disorder	0.00245	0.0114	CbGeAlD
Droxidopa—ADRA2C—nervous system—bipolar disorder	0.00241	0.0112	CbGeAlD
Droxidopa—ADRA1A—cerebellum—bipolar disorder	0.00238	0.0111	CbGeAlD
Droxidopa—ADRA2A—thyroid gland—bipolar disorder	0.00229	0.0106	CbGeAlD
Droxidopa—ADRA2C—cerebellum—bipolar disorder	0.00227	0.0105	CbGeAlD
Droxidopa—Dopamine—COMT—bipolar disorder	0.00212	0.0672	CrCbGaD
Droxidopa—SLC6A2—brain—bipolar disorder	0.00208	0.00967	CbGeAlD
Droxidopa—ADRA1A—brain—bipolar disorder	0.00194	0.00899	CbGeAlD
Droxidopa—ADRA2A—nervous system—bipolar disorder	0.00193	0.00894	CbGeAlD
Droxidopa—L-DOPA—DRD4—bipolar disorder	0.00185	0.0586	CrCbGaD
Droxidopa—ADRA2C—brain—bipolar disorder	0.00185	0.00856	CbGeAlD
Droxidopa—ADRA2A—cerebellum—bipolar disorder	0.00181	0.00841	CbGeAlD
Droxidopa—Dopamine—DRD4—bipolar disorder	0.00172	0.0545	CrCbGaD
Droxidopa—Dopamine—MAOA—bipolar disorder	0.0016	0.0507	CrCbGaD
Droxidopa—L-DOPA—DRD3—bipolar disorder	0.00159	0.0505	CrCbGaD
Droxidopa—L-DOPA—DRD1—bipolar disorder	0.00156	0.0496	CrCbGaD
Droxidopa—Dopamine—DRD3—bipolar disorder	0.00148	0.047	CrCbGaD
Droxidopa—ADRA2A—brain—bipolar disorder	0.00147	0.00683	CbGeAlD
Droxidopa—Dopamine—DRD1—bipolar disorder	0.00145	0.0461	CrCbGaD
Droxidopa—Dopamine—SLC6A3—bipolar disorder	0.00138	0.0437	CrCbGaD
Droxidopa—Dopamine—HTR1A—bipolar disorder	0.00121	0.0383	CrCbGaD
Droxidopa—L-DOPA—DRD2—bipolar disorder	0.0011	0.035	CrCbGaD
Droxidopa—Norepinephrine—DRD2—bipolar disorder	0.0011	0.035	CrCbGaD
Droxidopa—Dopamine—SLC6A4—bipolar disorder	0.00103	0.0327	CrCbGaD
Droxidopa—Dopamine—DRD2—bipolar disorder	0.00103	0.0325	CrCbGaD
Droxidopa—ADRA1A—Signaling by GPCR—DRD4—bipolar disorder	8.79e-05	0.000117	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—ADM—bipolar disorder	8.76e-05	0.000116	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—HTR2C—bipolar disorder	8.69e-05	0.000115	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD1—bipolar disorder	8.69e-05	0.000115	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—ADM—bipolar disorder	8.68e-05	0.000115	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—CACNA1C—bipolar disorder	8.64e-05	0.000115	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—ADM—bipolar disorder	8.57e-05	0.000114	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—HTR2A—bipolar disorder	8.57e-05	0.000114	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TSHB—bipolar disorder	8.54e-05	0.000113	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PDE4B—bipolar disorder	8.54e-05	0.000113	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TACR1—bipolar disorder	8.54e-05	0.000113	CbGpPWpGaD
Droxidopa—DDC—Metabolism—POMC—bipolar disorder	8.52e-05	0.000113	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TRPC3—bipolar disorder	8.5e-05	0.000113	CbGpPWpGaD
Droxidopa—DDC—Metabolism—INS—bipolar disorder	8.47e-05	0.000113	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—ADCY2—bipolar disorder	8.46e-05	0.000112	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PDE4B—bipolar disorder	8.46e-05	0.000112	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TSHB—bipolar disorder	8.46e-05	0.000112	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TACR1—bipolar disorder	8.46e-05	0.000112	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PIK3C2A—bipolar disorder	8.42e-05	0.000112	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD3—bipolar disorder	8.41e-05	0.000112	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—DRD2—bipolar disorder	8.38e-05	0.000111	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TRPC3—bipolar disorder	8.37e-05	0.000111	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TSHB—bipolar disorder	8.35e-05	0.000111	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TACR1—bipolar disorder	8.35e-05	0.000111	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PDE4B—bipolar disorder	8.35e-05	0.000111	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—POMC—bipolar disorder	8.29e-05	0.00011	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—ADCY2—bipolar disorder	8.27e-05	0.00011	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—DRD2—bipolar disorder	8.19e-05	0.000109	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD4—bipolar disorder	8.17e-05	0.000108	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—ADM—bipolar disorder	8.11e-05	0.000108	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—ADM—bipolar disorder	7.98e-05	0.000106	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TSHB—bipolar disorder	7.9e-05	0.000105	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TACR1—bipolar disorder	7.9e-05	0.000105	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PDE4B—bipolar disorder	7.9e-05	0.000105	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CLOCK—bipolar disorder	7.88e-05	0.000105	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—NRG1—bipolar disorder	7.82e-05	0.000104	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—HTR2A—bipolar disorder	7.8e-05	0.000104	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—HTR2A—bipolar disorder	7.78e-05	0.000103	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PDE4B—bipolar disorder	7.78e-05	0.000103	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TACR1—bipolar disorder	7.78e-05	0.000103	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TSHB—bipolar disorder	7.78e-05	0.000103	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—HTR1A—bipolar disorder	7.76e-05	0.000103	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—HTR2A—bipolar disorder	7.73e-05	0.000103	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—ADCY2—bipolar disorder	7.69e-05	0.000102	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—TPH2—bipolar disorder	7.68e-05	0.000102	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CACNB2—bipolar disorder	7.68e-05	0.000102	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—TSHB—bipolar disorder	7.68e-05	0.000102	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TAC1—bipolar disorder	7.64e-05	0.000101	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—HTR2A—bipolar disorder	7.63e-05	0.000101	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD2—bipolar disorder	7.61e-05	0.000101	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—SNAP25—bipolar disorder	7.55e-05	0.0001	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—DPYD—bipolar disorder	7.55e-05	0.0001	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—HTR2C—bipolar disorder	7.49e-05	9.95e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD1—bipolar disorder	7.49e-05	9.95e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TRPC3—bipolar disorder	7.43e-05	9.87e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—NTRK2—bipolar disorder	7.29e-05	9.68e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD3—bipolar disorder	7.25e-05	9.63e-05	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—HTR2A—bipolar disorder	7.22e-05	9.59e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—GSK3A—bipolar disorder	7.22e-05	9.59e-05	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—HTR2A—bipolar disorder	7.11e-05	9.44e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ADM—bipolar disorder	7.09e-05	9.41e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—HTR2A—bipolar disorder	7.09e-05	9.41e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HTR1A—bipolar disorder	7.07e-05	9.39e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—HTR2A—bipolar disorder	7.05e-05	9.37e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD4—bipolar disorder	7.04e-05	9.35e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—HTR2A—bipolar disorder	7.02e-05	9.33e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CACNA1C—bipolar disorder	7.02e-05	9.32e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HTR1A—bipolar disorder	7e-05	9.3e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TAC1—bipolar disorder	6.96e-05	9.24e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—HTR2A—bipolar disorder	6.93e-05	9.21e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HTR1A—bipolar disorder	6.91e-05	9.18e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TSHB—bipolar disorder	6.91e-05	9.17e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PDE4B—bipolar disorder	6.91e-05	9.17e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TACR1—bipolar disorder	6.91e-05	9.17e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TRPC3—bipolar disorder	6.9e-05	9.17e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TAC1—bipolar disorder	6.9e-05	9.16e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PIK3C2A—bipolar disorder	6.84e-05	9.09e-05	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—POMC—bipolar disorder	6.84e-05	9.09e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HTR2C—bipolar disorder	6.82e-05	9.06e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD1—bipolar disorder	6.82e-05	9.06e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TAC1—bipolar disorder	6.81e-05	9.04e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD1—bipolar disorder	6.76e-05	8.98e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HTR2C—bipolar disorder	6.76e-05	8.98e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—ADCY2—bipolar disorder	6.69e-05	8.88e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD1—bipolar disorder	6.68e-05	8.87e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HTR2C—bipolar disorder	6.68e-05	8.87e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NTRK2—bipolar disorder	6.64e-05	8.82e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—ADCY2—bipolar disorder	6.63e-05	8.8e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD3—bipolar disorder	6.61e-05	8.78e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TCF7L2—bipolar disorder	6.61e-05	8.77e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ADM—bipolar disorder	6.59e-05	8.75e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—GSK3A—bipolar disorder	6.58e-05	8.74e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NTRK2—bipolar disorder	6.58e-05	8.74e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD2—bipolar disorder	6.56e-05	8.71e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—HTR2A—bipolar disorder	6.56e-05	8.71e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD3—bipolar disorder	6.55e-05	8.7e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HTR1A—bipolar disorder	6.54e-05	8.69e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—GSK3A—bipolar disorder	6.52e-05	8.66e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NTRK2—bipolar disorder	6.49e-05	8.63e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD3—bipolar disorder	6.47e-05	8.59e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—HTR2A—bipolar disorder	6.46e-05	8.57e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TAC1—bipolar disorder	6.44e-05	8.55e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—GSK3A—bipolar disorder	6.44e-05	8.55e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HTR1A—bipolar disorder	6.44e-05	8.55e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TSHB—bipolar disorder	6.42e-05	8.52e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PDE4B—bipolar disorder	6.42e-05	8.52e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TACR1—bipolar disorder	6.42e-05	8.52e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD4—bipolar disorder	6.42e-05	8.52e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD4—bipolar disorder	6.36e-05	8.44e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TAC1—bipolar disorder	6.34e-05	8.42e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD1—bipolar disorder	6.32e-05	8.39e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HTR2C—bipolar disorder	6.32e-05	8.39e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—HTR2A—bipolar disorder	6.31e-05	8.39e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD4—bipolar disorder	6.28e-05	8.34e-05	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—POMC—bipolar disorder	6.23e-05	8.28e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD1—bipolar disorder	6.22e-05	8.26e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HTR2C—bipolar disorder	6.22e-05	8.26e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—POMC—bipolar disorder	6.21e-05	8.25e-05	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—POMC—bipolar disorder	6.18e-05	8.2e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NTRK2—bipolar disorder	6.15e-05	8.16e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—SNAP25—bipolar disorder	6.14e-05	8.15e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD3—bipolar disorder	6.12e-05	8.13e-05	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—POMC—bipolar disorder	6.1e-05	8.1e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—GSK3A—bipolar disorder	6.09e-05	8.09e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NTRK2—bipolar disorder	6.05e-05	8.03e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—ADCY2—bipolar disorder	6.04e-05	8.02e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD3—bipolar disorder	6.02e-05	8e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TCF7L2—bipolar disorder	6.02e-05	7.99e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—GSK3A—bipolar disorder	5.99e-05	7.96e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—ADCY2—bipolar disorder	5.99e-05	7.95e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD2—bipolar disorder	5.98e-05	7.94e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TCF7L2—bipolar disorder	5.96e-05	7.92e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—NTRK1—bipolar disorder	5.94e-05	7.89e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD4—bipolar disorder	5.94e-05	7.89e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD2—bipolar disorder	5.92e-05	7.87e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—ADCY2—bipolar disorder	5.91e-05	7.85e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TCF7L2—bipolar disorder	5.89e-05	7.82e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—HTR2A—bipolar disorder	5.87e-05	7.79e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD2—bipolar disorder	5.85e-05	7.77e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD4—bipolar disorder	5.85e-05	7.76e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—S100B—bipolar disorder	5.77e-05	7.67e-05	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—POMC—bipolar disorder	5.77e-05	7.66e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—HTR2A—bipolar disorder	5.73e-05	7.62e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—COMT—bipolar disorder	5.73e-05	7.6e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HTR1A—bipolar disorder	5.72e-05	7.59e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—MAOA—bipolar disorder	5.68e-05	7.55e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—GSK3B—bipolar disorder	5.68e-05	7.54e-05	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—POMC—bipolar disorder	5.68e-05	7.54e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—POMC—bipolar disorder	5.66e-05	7.52e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—POMC—bipolar disorder	5.63e-05	7.48e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TAC1—bipolar disorder	5.63e-05	7.48e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—POMC—bipolar disorder	5.61e-05	7.45e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—INS—bipolar disorder	5.6e-05	7.44e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—ADCY2—bipolar disorder	5.59e-05	7.42e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TCF7L2—bipolar disorder	5.57e-05	7.4e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—POMC—bipolar disorder	5.54e-05	7.35e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD2—bipolar disorder	5.53e-05	7.35e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD1—bipolar disorder	5.52e-05	7.33e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HTR2C—bipolar disorder	5.52e-05	7.33e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—ADCY2—bipolar disorder	5.5e-05	7.31e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TCF7L2—bipolar disorder	5.48e-05	7.28e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD2—bipolar disorder	5.45e-05	7.23e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—ADCY2—bipolar disorder	5.43e-05	7.21e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NTRK1—bipolar disorder	5.41e-05	7.19e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NTRK2—bipolar disorder	5.37e-05	7.13e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NTRK1—bipolar disorder	5.36e-05	7.12e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD3—bipolar disorder	5.35e-05	7.1e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—HTR2A—bipolar disorder	5.33e-05	7.08e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—GSK3A—bipolar disorder	5.32e-05	7.07e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HTR1A—bipolar disorder	5.31e-05	7.06e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NTRK1—bipolar disorder	5.29e-05	7.03e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—S100B—bipolar disorder	5.26e-05	6.99e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—POMC—bipolar disorder	5.24e-05	6.96e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TAC1—bipolar disorder	5.23e-05	6.95e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—S100B—bipolar disorder	5.21e-05	6.92e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD4—bipolar disorder	5.19e-05	6.9e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—POMC—bipolar disorder	5.16e-05	6.85e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—S100B—bipolar disorder	5.15e-05	6.84e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HTR2C—bipolar disorder	5.13e-05	6.81e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD1—bipolar disorder	5.13e-05	6.81e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—NRG1—bipolar disorder	5.1e-05	6.77e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—POMC—bipolar disorder	5.04e-05	6.7e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NTRK1—bipolar disorder	5.01e-05	6.65e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NTRK2—bipolar disorder	4.99e-05	6.63e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD3—bipolar disorder	4.97e-05	6.6e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—GSK3A—bipolar disorder	4.95e-05	6.57e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NTRK1—bipolar disorder	4.93e-05	6.55e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ADCY2—bipolar disorder	4.89e-05	6.49e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TCF7L2—bipolar disorder	4.87e-05	6.47e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—S100B—bipolar disorder	4.87e-05	6.47e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD2—bipolar disorder	4.84e-05	6.42e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD4—bipolar disorder	4.82e-05	6.41e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—S100B—bipolar disorder	4.79e-05	6.36e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—POMC—bipolar disorder	4.69e-05	6.22e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—COMT—bipolar disorder	4.65e-05	6.18e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NRG1—bipolar disorder	4.64e-05	6.17e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—MTHFR—bipolar disorder	4.63e-05	6.15e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—MAOA—bipolar disorder	4.62e-05	6.13e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NRG1—bipolar disorder	4.6e-05	6.11e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—HTR2A—bipolar disorder	4.6e-05	6.1e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—POMC—bipolar disorder	4.58e-05	6.08e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NRG1—bipolar disorder	4.54e-05	6.03e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ADCY2—bipolar disorder	4.54e-05	6.03e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TCF7L2—bipolar disorder	4.53e-05	6.01e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD2—bipolar disorder	4.49e-05	5.97e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NTRK1—bipolar disorder	4.38e-05	5.82e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NRG1—bipolar disorder	4.3e-05	5.71e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—S100B—bipolar disorder	4.26e-05	5.65e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—POMC—bipolar disorder	4.26e-05	5.65e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NRG1—bipolar disorder	4.23e-05	5.62e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HTR2A—bipolar disorder	4.19e-05	5.56e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HTR2A—bipolar disorder	4.15e-05	5.51e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HTR2A—bipolar disorder	4.1e-05	5.44e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NTRK1—bipolar disorder	4.07e-05	5.4e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—S100B—bipolar disorder	3.96e-05	5.25e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HTR2A—bipolar disorder	3.88e-05	5.15e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HTR2A—bipolar disorder	3.81e-05	5.07e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—MTHFR—bipolar disorder	3.76e-05	4.99e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NRG1—bipolar disorder	3.76e-05	4.99e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—POMC—bipolar disorder	3.7e-05	4.92e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—GSK3B—bipolar disorder	3.7e-05	4.91e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—INS—bipolar disorder	3.68e-05	4.89e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—POMC—bipolar disorder	3.67e-05	4.87e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—INS—bipolar disorder	3.65e-05	4.85e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NRG1—bipolar disorder	3.49e-05	4.64e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HTR2A—bipolar disorder	3.39e-05	4.5e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—GSK3B—bipolar disorder	3.37e-05	4.48e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—POMC—bipolar disorder	3.34e-05	4.44e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—GSK3B—bipolar disorder	3.34e-05	4.44e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—INS—bipolar disorder	3.33e-05	4.42e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—POMC—bipolar disorder	3.31e-05	4.4e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—GSK3B—bipolar disorder	3.3e-05	4.38e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—INS—bipolar disorder	3.29e-05	4.38e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—POMC—bipolar disorder	3.27e-05	4.34e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—INS—bipolar disorder	3.25e-05	4.32e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HTR2A—bipolar disorder	3.15e-05	4.18e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—GSK3B—bipolar disorder	3.12e-05	4.14e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—POMC—bipolar disorder	3.09e-05	4.11e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—INS—bipolar disorder	3.08e-05	4.09e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—GSK3B—bipolar disorder	3.07e-05	4.08e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—POMC—bipolar disorder	3.05e-05	4.05e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—INS—bipolar disorder	3.03e-05	4.02e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—POMC—bipolar disorder	3.01e-05	3.99e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—INS—bipolar disorder	2.99e-05	3.97e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—GSK3B—bipolar disorder	2.73e-05	3.62e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—POMC—bipolar disorder	2.71e-05	3.59e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—INS—bipolar disorder	2.69e-05	3.57e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—GSK3B—bipolar disorder	2.53e-05	3.37e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—POMC—bipolar disorder	2.51e-05	3.34e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—INS—bipolar disorder	2.5e-05	3.32e-05	CbGpPWpGaD
